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“B” aware: Memory lane access is restricted!
Ruth Kennedy and Ulf Klein
Understanding the molecular mechanisms that govern the differentiation of high-affinity germinal center (GC) B cells into
memory B cells versus plasma cells is a major quest of adaptive immunity. In this issue, Toboso-Navasa et al. (https://doi.org/
10.1084/jem.20191933) provide evidence that the MYC–MIZ1 transcriptional repressor complex restricts the differentiation
of GC B cells into MBCs.
The germinal center (GC) is the workhorse
of antibody-dependent adaptive immunity
that manufactures the mediators of the hu-
moral immune response: high-affinity
plasma cells (PCs) that eliminate the invad-
ing pathogen and memory B cells (MBCs)
that, upon reinfection, rapidly mount a
pathogen-specific antibody response. Within
the GC microenvironment, B cells recirculate
between two histologically and functionally
defined zones: the dark zone (DZ) and the
light zone (LZ). DZ B cells diversify their
immunoglobulin variable region genes by
somatic hypermutation (SHM) and migrate
to the LZ, where they differentiate into LZ
B cells, which are selected for improved an-
tigen binding under the guidance of T follic-
ular helper cells (Victora and Nussenzweig,
2012).
In essence, three cellular fates await a
positively selected LZ B cell: recirculation to
the DZ to undergo iterative rounds of pro-
liferation and SHM, or exiting the GC as an
MBC or PC. All three transitions are asso-
ciated with a drastic change in cell pheno-
type. A major question of GC biology is,
therefore, how are these decision points
molecularly controlled? What mechanisms
instruct an LZ B cell to differentiate into a
DZ B cell, MBC, or PC? Or, conversely, are
there molecular “brakes” that prevent certain
developmental transitions? Toboso-Navasa
et al. have now provided compelling evidence
that the MYC and MIZ1 (MYC-interacting
zinc-finger protein 1, ZBTB17) transcription
factors jointly regulate the fate of positively
selected GC B cells, in that they restrict MBC
differentiation while promoting effective GC
expansion and PC differentiation (Toboso-
Navasa et al., 2020).
The congregation of three lines of
reasoning drove Toboso-Navasa et al. to
investigate the role of MIZ1 in MBC dif-
ferentiation. First, the up-regulation of
MYC expression in positively selected LZ
B cells is required both for licensing cell
cycle progression before LZ–DZ reentry and
for PC differentiation (Dominguez-Sola
et al., 2012; Calado et al., 2012; Ise et al.,
2018). Second, a phenotypically distinct,
MYC-negative LZ population that consists of
quiescent LZ B cells, many of which express
the transcription factor BACH2 that favors
MBC differentiation (Shinnakasu et al.,
2016), is enriched for MBC precursors
(Laidlaw et al., 2017; Wang et al., 2017).
Thus, the absence of MYC expression in
MBC precursors suggested to Toboso-
Navasa et al. that MYC activity in posi-
tively selected LZ B cells may curb MBC
differentiation. Third, how would MYC do
this? A clue comes from human cancers,
where MYC was shown to form a complex
with MIZ1 that displaces key MIZ1 co-
activators, thus abrogating the MIZ1
transcriptional program, which includes
negative cell cycle regulators such as cyclin-
dependent kinase inhibitor genes (Wiese
et al., 2013). Knotting these strings of in-
formation together, Toboso-Navasa et al.
(2020) hypothesized that MYC–MIZ1 activ-
ity in positively selected LZ B cells may
positively regulate proliferation and restrict
MBC differentiation.
Their hypothesis passed the essential
first hurdle: immunofluorescence analysis
of spleen sections from mice immunized
with a T cell–dependent antigen revealed
coexpression of MIZ1 and MYC in positively
selected LZ B cells. This finding provided the
rationale for elucidating the in vivo function
of the MYC–MIZ1 complex in GC B cell de-
velopment. Central to the study was a
transgenic allele harboring an endogenous
MYC mutant (valine 394 is replaced with
aspartic acid, V—>D; MycVD mice; Saba
et al., 2011) that abrogates the association
of MYC with MIZ1 (top panel of image)
while retaining binding to MYC’s obligatory
“partner” MAX and the ability to transcrip-
tionally activate. Transcriptional analysis of
flow-cytometrically isolated LZ B cells of
MycVD mice revealed vastly different gene
expression profiles compared with MycWT
control mice. By integrating RNA-seq data
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with ChIP-seq data for both MYC and MIZ,
known MIZ1-target genes bound by MYC
were found to be up-regulated in the mutant
mice that in the wild-type context were re-
pressed by MYC-MIZ1 complexes, revealing
a distinct function forMYC–MIZ1 complexes
in positively selected LZ B cells.
Now, to what extent does abrogation of
the MYC–MIZ1 complex affect the GC B cell
reaction in immunized MycVD mice? At the
height of the GC reaction, both the fraction
and number of GC B cells in MycVD mice
were significantly reduced compared with
MycWT mice, as was the size of individual
GCs. Nevertheless, the number of GC foci
was equivocal between mutant and wild-
type mice, indicating that the MYC–MIZ1
complex is required for GC expansion but
dispensable during GC formation. Similarly,
Toboso-Navasa et al. (2020) detected fewer
PCs in the MycVD mice relative to wild-type
mice, which is a relevant finding since
positively selected (MYC+) LZ B cells also
contain PC precursors (Ise et al., 2018).
Regarding functional consequences,
Toboso-Navasa et al. (2020) did not detect
changes in GC B cell survival in the absence
of MYC–MIZ1 complexes. A first clue for a
potential role of the complex in cell cycle
regulation came from a gene set enrichment
analysis, which revealed that LZ B cells from
wild-type animals showed enrichment of
gene sets for “G1–S phase transition”; con-
versely, the transcriptional data from the
mutants were enriched for gene sets of the
category “cell cycle arrest.” Indeed, pulse
experiments where the nucleoside analogue
EdU was incorporated into the DNA of ac-
tively proliferating cells revealed impaired
cell cycle engagement in MycVD mice com-
pared with their wild-type counterparts.
So, MYC–MIZ1 complexes facilitate LZ–DZ
recycling of positively selected LZ B cells
by regulating the expression of cell
cycle–associated genes.
A series of well-conceived experiments
then provided compelling evidence for the
role of the MYC–MIZ1 complex in restrict-
ing MBC differentiation. Comparative gene
expression analysis identified an altered
transcriptional program in LZ GC B cells
lacking the MYC–MIZ1 complex that in part
is characterized by the up-regulation of
MBC-associated genes. In accordance, trac-
ing of MBCs (IgG1+CD273+) in immunized
MycVD versus MycWT mice using two dif-
ferent experimental systems revealed in-
creased fractions and numbers of MBCs in
the mutant mice (bottom panel of image).
The majority of these MBCs originated in
the GC, as demonstrated by EdU pulse ex-
periments showing that increased MBC
differentiation was linked to GC expansion.
What about the quality of the MBCs de-
veloping in MycVD mice? To address this
question, Toboso-Navasa et al. (2020) em-
ployed a transgenic B cell receptor (BCR)
that is commonly used to analyze antigen
affinity maturation (SWHEL allelic system;
Paus et al., 2006) and that allows monitor-
ing of the generation of hen egg lysozyme
(HEL)–specific B cells by the occurrence of
an amino acid exchange that increases HEL
affinity by 100-fold. It emerged that MBCs
in MycVD versus MycWT mice had fewer
SHMs in their antibody genes and a signif-
icant reduction in the fraction of high-
affinity BCRs. A conceivable explanation
for the observed decrease in HEL affinity in
the absence of MYC–MIZ1 complexes might
be a transitory delay in affinity maturation.
However, this possibility was ruled out
since MycVD mice lacking AID (an enzyme
critical for SHM) similarly showed an in-
creased fraction of MBCs and a concomitant
reduction in recycling GC B cells compared
with the wild-type counterparts, indicating
that the activity of the MYC–MIZ1 complex
is cell intrinsic and follows a timed program.
Clearly, this is an intriguing observation
because it may imply that the MYC–MIZ1
complex is an evolutionary addition specif-
ically aimed at restricting the exit of B cells
from the GC. As Toboso-Navasa et al. fur-
ther point out, AID and the MYC–MIZ1
complexes appeared in vertebrate evolution
around the same time. One may envisage
that the joint activities of MYC–MIZ1 and
AID allowed for an effective GC expansion
In positively selected LZ B cells within the GC, MYC–MIZ1 complexes are required for effective GC
expansion and PC formation and restrict the formation of MBCs. (Top) Experimental model used by
Toboso-Navasa et al. (2020) and observed transcriptional consequences in positively selected LZ B cells.
(Top left) In LZ B cells, the MYC–MIZ1 complex represses MIZ1 target genes. (Top right) A V394D amino
acid exchange in MYC protein impairs binding of MIZ1 to MYC, leading to the expression of MIZ1 target
genes in LZ B cells. (Bottom) Cellular compartment output as the consequences of the repression of MIZ1
target genes in positively selected LZ B cells (left panel), and the expression of MIZ1 target genes in LZ
B cells where MYC–MIZ1 binding is impaired (right panel). Quantitative changes (not to scale) in the
compartments of the descendants of positively selected LZ B cells, i.e., recirculating LZ B cells, MBCs,
and PCs, are indicated. In MBCs developing in the mutant mice, the affinity of the BCRs is reduced
compared with the wild-type setting, here for simplicity indicated as low- versus high-affinity BCRs,
respectively.
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through facilitating repeated rounds of SHM
and selection, thereby substantially im-
proving the affinity of antigen-specific
MBCs and PCs. In this regard, an equiva-
lent molecular mechanism that also keeps
B cells in the “GC roundabout” and that acts
in the PC differentiation arm of GC devel-
opment is provided by Casitas B-lineage
lymphoma (CBL) ubiquitin ligases (Li
et al., 2018).
The latter observation—and the work of
others that provided insights into the mo-
lecular control of GC B cell development
that cannot be discussed due to space
limitations—highlights the complexity of
this B cell developmental stage and reminds
us that we are still lacking a deep under-
standing of why and how the positively
selected LZ B cell follows a particular dif-
ferentiation route. For example, it is well
established that over the time course of a GC
reaction (which lasts for several weeks), the
major cellular output switches from pre-
dominantly MBCs early on to predomi-
nantly PCs at late stages (Shinnakasu et al.,
2016; Weisel et al., 2016). Thus, the findings
of Toboso-Navasa et al. (2020) that the
MYC–MIZ1 complex restricts MBC differ-
entiation at early andmid–time points of the
GC reaction are seemingly at odds with this
observation. However, despite the temporal
differences in the cellular output, bothMBCs
and PCs continuously exit the GC during the
immune response (Blink et al., 2005), indi-
cating that the MYC–MIZ1-associated re-
striction of MBC differentiation is likely the
subject of a nuanced fine-tuning by multiple
parallel mechanisms within the LZ B cell. It
seems probable that the fate decisions
within an individual LZ B cell, rather than
following a binary “on-off” switch, are con-
tingent on the integration of various inputs
that establish a gradient of regulation that
ultimately reaches a tipping point.
The ultimate expectation of under-
standing how the differentiation of a posi-
tively selected LZ B cell is controlled at the
molecular level is to exploit this knowledge
for the manipulation of the humoral im-
mune response, with particular relevance
for vaccine development. This is an ambi-
tious undertaking, but the new findings by
Toboso-Navasa et al. (2020) may bring us
one step closer to this goal; interfering with
MYC–MIZ1 complexes during an immune
response may yield an increased population
size of MBCs with overall lower, but much
broader, antigen affinity. A broad-spectrum
humoral memory induced by vaccination
could be advantageous in the recognition of
sub-strains or mutants of the immunizing
pathogen (Victora and Wilson, 2015), and
further rounds of affinity maturation may
provide effective protection. It is therefore
not outside the bounds of possibility to en-
visage a therapeutic manipulation of the
MYC—MIZ1 axis that would increase MBC
output alongside vaccine delivery.
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